CN103285304B - Medicine for treating infection after lung cancer chemotherapy - Google Patents
Medicine for treating infection after lung cancer chemotherapy Download PDFInfo
- Publication number
- CN103285304B CN103285304B CN201310170876.6A CN201310170876A CN103285304B CN 103285304 B CN103285304 B CN 103285304B CN 201310170876 A CN201310170876 A CN 201310170876A CN 103285304 B CN103285304 B CN 103285304B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- fructus
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention provides a medicine for treating infection after lung cancer chemotherapy. The medicine is prepared from the following raw materials: 24 parts of astragalus mongholicus, 20 parts of codonopsis pilosula, 15 parts of rhizoma atractylodis macrocephalae, 24 parts of poria cocos, 12 parts of dried tangerine or orange peel, 9 parts of pinellia ternata, 12 parts of chrysoidine, 12 parts of honey-fried folium meriabotryae, 9 parts of scutellaria baicalensis, 12 parts of angelica decursiva, 9 parts of stir-baked semen persicae, 9 parts of stir-baked semen armeniacae amarum, 9 parts of tendril-leaved fritillary bulb, 9 parts of fritillaria thunnbergii miq, 12 parts of salvia miltiorrhiza, 12 parts of amomum villosum, 9 parts of alpinia officinarum hance, 18 parts of perilla leaf, 18 parts of fructus lycii, 24 parts of yam, 15 parts of ophiopogon japonicus, 6 parts of periostracum cicada, 12 parts of Chinese olive, 15 parts of hedyotis diffusa willd, 15 parts of scutellaria barbata, 24 parts of euryale ferox salisb, 12 parts of forsythia suspensa, 18 parts of ramulus loranthi, 30 parts of sanguisorba officinalis, 9 parts of rhizoma coptidis, 12 parts of fructus corni, 10 parts of sophora flavescens, 12 parts of mulberry, 30 parts of semen cuscutae and 24 parts of hairyvein agrimony. The medicine provided by the invention is effective in treatment and can be applied to clinical treatment of the infection after the lung cancer chemotherapy.
Description
Technical field
The present invention relates to a kind of medicine, be specifically related to a kind of medicine for the treatment of lung cancer chemotherapy postoperative infection.
Background technology
Pulmonary carcinoma belongs to a kind of malignant tumor, and its sickness rate increases year by year.Along with the increase of patients with lung cancer number, increasing patient starts to carry out chemotherapy, but in chemotherapy process, because immunity is poor or the situation such as pulmonary insufficiency causes the generation of pulmonary infection condition of illness, severe patient even can cause death because of pulmonary infection after chemotherapy.Visible pulmonary infection is the extremely serious disease of bringing out in lung cancer chemotherapy process.And lung cancer chemotherapy postoperative infection is different from general pulmonary infection, the medicine of general pulmonary infection to chemotherapy after the curative effect of pulmonary infection not remarkable, in prior art, also rarely have the medicine for lung cancer chemotherapy postoperative infection.
Summary of the invention
In order to solve the problems of the technologies described above, the invention provides a kind of medicine for the treatment of lung cancer chemotherapy postoperative infection.
Technical scheme of the present invention is as follows: a kind of medicine for the treatment of lung cancer chemotherapy postoperative infection, medicine by following weight portion is prepared from: the Radix Astragali 24, Radix Codonopsis 20, Rhizoma Atractylodis Macrocephalae (parched) 15, Poria 24, Pericarpium Citri Reticulatae 12, the Rhizoma Pinelliae 9, Exocarpium Citri Rubrum 12, Folium Eriobotryae (processed) 12, Radix Scutellariae 9, Radix Peucedani 12, Semen Persicae (parched) 9, Semen Armeniacae Amarum (parched) 9, Bulbus Fritillariae Cirrhosae 9, Bulbus Fritillariae Thunbergii 9, Radix Salviae Miltiorrhizae 12, Fructus Amomi 12, Rhizoma Alpiniae Officinarum 9, Folium Perillae 18, Fructus Lycii 18, Rhizoma Dioscoreae 24, Radix Ophiopogonis 15, Periostracum Cicadae 6, Fructus Canarii 12, Herba Hedyotidis Diffusae 15, Herba Scutellariae Barbatae 15, Semen Euryales 24, Fructus Forsythiae 12, Herba Taxilli 18, Radix Sanguisorbae 30, Rhizoma Coptidis 9, Fructus Corni 12, Radix Sophorae Flavescentis 10, Fructus Mori 12, Semen Cuscutae 30, Herba Agrimoniae 24.
Instructions of taking: conventional water extraction, day potion.
During Chemotherapy of Patients with Lung Cancer, very easily because of complicated underlying diseases or Abwehrkraft des Koepers is poor etc. that factor causes pulmonary infection.After chemotherapy, pulmonary infection symptom mainly comprises mixed infection, superinfection and gram positive bacterial infection etc.Because bacterial infection is stronger, virulence is larger, easily causes tumor deterioration or patient's quality of life to decline.In medicine of the present invention each crude drug share there is infection, cough-relieving, heat clearing away, the effect of relievining asthma and building up resistance.Scientific formulation of the present invention, has significant curative effect through clinical verification.
Clinical data
1.1 physical data
Choose patients with pulmonary infection after in March, 2012-2013 routine lung cancer chemotherapy in year March 50, wherein male 30 examples, female's 20 examples; 48 ~ 70 years old age, average (56 ± 2.51) year, main clinic symptoms is hyperpyrexia, cough, silt expectorant etc., auscultation of lung can be found dry wet sound of vomiting sound, routine blood test is abnormal, CT shows pulmonary infection.All patients are divided into two groups at random, every group of 25 examples, the physical data such as sex to two groups of patients, age, symptom, course of disease compares, and difference not statistically significant (p>0.05), has comparability.
1.2 method
Row routine urinalysis, blood chemical examination, Sputum bacterial culture, drug sensitivity assay, x line and breast CT inspection before and after two groups of patient treatments, as Comparison of therapeutic foundation before and after treatment.B group patient gives and dispels and cough, stop in the situation such as expectorant, suitable rest at reinforcement idiotrophic, is that patient selects the most responsive antibiotic to carry out Primary Care according to drug sensitive experiment result; A group is taken medicine of the present invention.It is a course for the treatment of that above two groups of patients all treat 10d continuously, adopts identical standard to carry out efficacy determination.
1.3 curative effect determinate standard
Effective: pulmonary infection transference cure, x line shows pulmonary infection foci disappearance.
Effective: pulmonary infection symptom is effectively improved, heating is gone down, loose cough's phenomenon alleviates, the moist sound of vomiting sound of asthma and pulmonary fades away, and x line shows that pulmonary infection focus has the trend of diminishing.
Invalid: still have pulmonary infection symptom, cough, expectoration do not alleviate, and still has heating and the moist sound of vomiting sound of pulmonary, x line shows that pulmonary infection focus still exists and even starts expansion.
Effectively total=effectively+effective.
1.4 statistical procedures
The data obtained adopt SPSS 13.0 statistical softwares carry out date processing, measurement data with (
± s), adopting t inspection, enumeration data adopts X
2inspection, P<0.05 is that difference has statistical significance.
2. result:
Single course of therapy Contrast on effect (result is as following table) after 2.1 liang of group patient pulmonary infections.
After single course of therapy, A group total effective rate is that 92%, B group total effective rate is 76%; Difference has significant (P<0.05)
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described further.
Embodiment 1
Take crude drug by following weight portion: the Radix Astragali 24, Radix Codonopsis 20, Rhizoma Atractylodis Macrocephalae (parched) 15, Poria 24, Pericarpium Citri Reticulatae 12, the Rhizoma Pinelliae 9, Exocarpium Citri Rubrum 12, Folium Eriobotryae (processed) 12, Radix Scutellariae 9, Radix Peucedani 12, Semen Persicae (parched) 9, Semen Armeniacae Amarum (parched) 9, Bulbus Fritillariae Cirrhosae 9, Bulbus Fritillariae Thunbergii 9, Radix Salviae Miltiorrhizae 12, Fructus Amomi 12, Rhizoma Alpiniae Officinarum 9, Folium Perillae 18, Fructus Lycii 18, Rhizoma Dioscoreae 24, Radix Ophiopogonis 15, Periostracum Cicadae 6, Fructus Canarii 12, Herba Hedyotidis Diffusae 15, Herba Scutellariae Barbatae 15, Semen Euryales 24, Fructus Forsythiae 12, Herba Taxilli 18, Radix Sanguisorbae 30, Rhizoma Coptidis 9, Fructus Corni 12, Radix Sophorae Flavescentis 10, Fructus Mori 12, Semen Cuscutae 30, Herba Agrimoniae 24.Add 10 times, 8 times water gagings to decoct twice, each 2 hours, filter, merging filtrate, being concentrated into relative density is 1.05-1.15.
Claims (1)
1. treat the medicine of lung cancer chemotherapy postoperative infection for one kind, it is characterized in that, medicine by following weight portion is prepared from: the Radix Astragali 24, Radix Codonopsis 20, Rhizoma Atractylodis Macrocephalae (parched) 15, Poria 24, Pericarpium Citri Reticulatae 12, the Rhizoma Pinelliae 9, Exocarpium Citri Rubrum 12, Folium Eriobotryae (processed) 12, Radix Scutellariae 9, Radix Peucedani 12, Semen Persicae (parched) 9, Semen Armeniacae Amarum (parched) 9, Bulbus Fritillariae Cirrhosae 9, Bulbus Fritillariae Thunbergii 9, Radix Salviae Miltiorrhizae 12, Fructus Amomi 12, Rhizoma Alpiniae Officinarum 9, Folium Perillae 18, Fructus Lycii 18, Rhizoma Dioscoreae 24, Radix Ophiopogonis 15, Periostracum Cicadae 6, Fructus Canarii 12, Herba Hedyotidis Diffusae 15, Herba Scutellariae Barbatae 15, Semen Euryales 24, Fructus Forsythiae 12, Herba Taxilli 18, Radix Sanguisorbae 30, Rhizoma Coptidis 9, Fructus Corni 12, Radix Sophorae Flavescentis 10, Fructus Mori 12, Semen Cuscutae 30, Herba Agrimoniae 24.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310170876.6A CN103285304B (en) | 2013-05-10 | 2013-05-10 | Medicine for treating infection after lung cancer chemotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310170876.6A CN103285304B (en) | 2013-05-10 | 2013-05-10 | Medicine for treating infection after lung cancer chemotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103285304A CN103285304A (en) | 2013-09-11 |
| CN103285304B true CN103285304B (en) | 2014-08-13 |
Family
ID=49087193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310170876.6A Expired - Fee Related CN103285304B (en) | 2013-05-10 | 2013-05-10 | Medicine for treating infection after lung cancer chemotherapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285304B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115317554B (en) * | 2022-09-07 | 2023-06-30 | 广西中医药大学第一附属医院 | Traditional Chinese medicine composition for treating neutrophil deficiency with fever after chemotherapy and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103589A (en) * | 1993-12-09 | 1995-06-14 | 卜荣安 | Plaster for treating respiratory system diseases |
| CN101703726A (en) * | 2009-11-19 | 2010-05-12 | 何玉伟 | Medicament for treating lung cancer |
-
2013
- 2013-05-10 CN CN201310170876.6A patent/CN103285304B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103589A (en) * | 1993-12-09 | 1995-06-14 | 卜荣安 | Plaster for treating respiratory system diseases |
| CN101703726A (en) * | 2009-11-19 | 2010-05-12 | 何玉伟 | Medicament for treating lung cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103285304A (en) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101147791B (en) | Traditional Chinese medicine preparation for enriching blood and its preparation method | |
| CN102755619A (en) | Traditional Chinese medicine health care product for treating chronic bronchitis | |
| CN103768398B (en) | Traditional Chinese medicine composition for treating advanced lung tumors | |
| CN103212006A (en) | Traditional Chinese medicine for treating chronic bronchitis | |
| CN104288315A (en) | Traditional Chinese medicine composition for resisting superbacteria NDM-1 drug resistance gene bacteria | |
| CN104189859A (en) | Traditional Chinese medicine for treating lung cancer | |
| CN103285304B (en) | Medicine for treating infection after lung cancer chemotherapy | |
| CN103263631B (en) | Traditional Chinese medicine composition for treating infection after lung cancer chemotherapy | |
| CN102920965A (en) | Traditional Chinese medicine water-bindered pill for treating advanced lung cancer | |
| CN102698128A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104189847A (en) | Traditional Chinese medicine for treating tuberculous exadative pleurisy | |
| CN104013918A (en) | Drug for treating gastric cancer | |
| CN103251827A (en) | Traditional Chinese medicine composition for treating diabetes mellitus and preparation method thereof | |
| CN101584770A (en) | Novel method for treating acne through heat clearing and blood cooling and activation of scutellaria, paeony and fresh rehmannia | |
| CN103520558B (en) | A kind of preparation method for the treatment of the pharmaceutical composition of children's's suppurative tonsillitis | |
| Hong et al. | Analysis of the cluster efficacy and prescription characteristics of traditional Chinese medicine intervention for non-small cell lung cancer based on a clustering algorithm | |
| CN109700931A (en) | A kind of drug and preparation method thereof for the concurrent celiothelioma of Chronic Obstructive Pulmonary Disease | |
| CN105641326A (en) | Treatment method for treating ulcerative colitis by combining codonopsis pilosula-radix astragali intestine-tonifying soup with ulcerative colitis enema liquid | |
| CN103893644A (en) | Traditional Chinese medicine water pill preparation for treating advanced lung cancer | |
| CN104491103A (en) | Traditional Chinese medicine composition for treating ulcerative colitis | |
| CN114028527A (en) | Traditional Chinese medicine composition for lung-tonifying and food retention-removing decoction | |
| CN104740566A (en) | Preparation for relieving skin inflammation, and preparation method and application thereof | |
| CN104623155A (en) | Traditional Chinese medicine composition for treating tumor | |
| CN116236538A (en) | Traditional Chinese medicine formula for treating phthisis | |
| CN111420005A (en) | Fragrant scented tea and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140813 Termination date: 20190510 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |